For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.

An Ohio State hematologist discusses a new trial comparing tovorafenib plus rituximab with standard cladribine-based treatment, and what quality of life means for patients.

Adding Anktiva to BCG led to better responses than BCG alone in people with high-risk bladder cancer who had not yet received BCG, the company said.

An Ohio State hematologist explains how she weighs chemotherapy against targeted drugs, what side effects patients should expect and why learning about this specific leukemia matters.

Leanne Citrone shares how a BRCA mutation, an elective mastectomy and a stage 2C ovarian cancer diagnosis shaped her outlook, anxiety and advice to others.

A colon cancer survivor who cared for her mother with lung cancer shares how she learned to speak up, plus tips for advocating for yourself or a loved one.

Medicare's Part D out-of-pocket cap rises to $2,400 in 2027. Here is what that means for people taking costly oral cancer drugs, how the monthly payment plan works with it and what to check before open enrollment ends Dec. 7.

Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.